Combined Tretinoin and Arsenic Trioxide for Patients With Newly Diagnosed Acute Promyelocytic Leukemia Followed by Risk-Adapted Postremission Therapy

This study is currently recruiting participants. (see Contacts and Locations)
Verified February 2015 by Memorial Sloan Kettering Cancer Center
Sponsor:
Collaborators:
Northwestern University
New York Presbyterian Hospital
University of Southern California
Princess Margaret Hospital, Canada
Information provided by (Responsible Party):
Memorial Sloan Kettering Cancer Center
ClinicalTrials.gov Identifier:
NCT01404949
First received: July 27, 2011
Last updated: February 9, 2015
Last verified: February 2015
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: July 2015
  Estimated Primary Completion Date: July 2015 (Final data collection date for primary outcome measure)